-
1
-
-
0035235736
-
Mitotic kinases as regulators of cell division and its checkpoints
-
Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001; 2: 21-32.
-
(2001)
Nat Rev Mol Cell Biol
, vol.2
, pp. 21-32
-
-
Nigg, E.A.1
-
2
-
-
2942615282
-
Polo-like kinases and the orchestration of cell division
-
Barr FA, Sillje HH, Nigg EA. Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 2004; 5: 429-440.
-
(2004)
Nat Rev Mol Cell Biol
, vol.5
, pp. 429-440
-
-
Barr, F.A.1
Sillje, H.H.2
Nigg, E.A.3
-
3
-
-
33645316142
-
Targeting polo-like kinase 1 for cancer therapy
-
Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6: 321-330.
-
(2006)
Nat Rev Cancer
, vol.6
, pp. 321-330
-
-
Strebhardt, K.1
Ullrich, A.2
-
4
-
-
0038624074
-
Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells
-
Liu X, Erikson RL. Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci USA 2003; 100: 5789-5794.
-
(2003)
Proc Natl Acad Sci USA
, vol.100
, pp. 5789-5794
-
-
Liu, X.1
Erikson, R.L.2
-
5
-
-
0037132736
-
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells
-
Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94: 1863-1877.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1863-1877
-
-
Spänkuch-Schmitt, B.1
Bereiter-Hahn, J.2
Kaufmann, M.3
Strebhardt, K.4
-
6
-
-
65649105075
-
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity
-
Rudolph D, Steegmaier M, Hoffmann M et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009; 15: 3094-3102.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 3094-3102
-
-
Rudolph, D.1
Steegmaier, M.2
Hoffmann, M.3
-
7
-
-
84900540918
-
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies
-
Lin C-C, Su W, Yen C-J et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous Polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 2014; 110: 2434-2440.
-
(2014)
Br J Cancer
, vol.110
, pp. 2434-2440
-
-
Lin, C.-C.1
Su, W.2
Yen, C.-J.3
-
8
-
-
84655164874
-
A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours
-
Schöffski P, Awada A, Dumez H et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer 2012; 48: 179-186.
-
(2012)
Eur J Cancer
, vol.48
, pp. 179-186
-
-
Schöffski, P.1
Awada, A.2
Dumez, H.3
-
9
-
-
84255215015
-
Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC
-
Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Onco Targets Ther 2011; 4: 43-58.
-
(2011)
Onco Targets Ther
, vol.4
, pp. 43-58
-
-
Ballas, M.S.1
Chachoua, A.2
-
10
-
-
0036984640
-
Role of angiogenesis in tumor growth and metastasis
-
Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15-18.
-
(2002)
Semin Oncol
, vol.29
, pp. 15-18
-
-
Folkman, J.1
-
11
-
-
84880212274
-
BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer
-
Rolfo C, Raez LE, Bronte G et al. BIBF 1120/nintedanib: a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin Investig Drugs 2013; 22: 1081-1088.
-
(2013)
Expert Opin Investig Drugs
, vol.22
, pp. 1081-1088
-
-
Rolfo, C.1
Raez, L.E.2
Bronte, G.3
-
12
-
-
84892967581
-
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
-
Reck M, Kaiser R, Mellemgaard A et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 2014; 15: 143-155.
-
(2014)
Lancet Oncol
, vol.15
, pp. 143-155
-
-
Reck, M.1
Kaiser, R.2
Mellemgaard, A.3
-
13
-
-
84886393615
-
Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy
-
Hanna NH, Kaiser R, Sullivan RN et al. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31(15s): 8034.
-
(2013)
J Clin Oncol
, vol.31
, Issue.15
, pp. 8034
-
-
Hanna, N.H.1
Kaiser, R.2
Sullivan, R.N.3
-
14
-
-
84947787434
-
Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC)
-
Kristensen G, Harter P, Trédan O et al. Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC). J Clin Oncol 2014; 32(15s): 5556.
-
(2014)
J Clin Oncol
, vol.32
, Issue.15
, pp. 5556
-
-
Kristensen, G.1
Harter, P.2
Trédan, O.3
-
15
-
-
74949090791
-
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors
-
Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res 2010; 16: 311-319.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 311-319
-
-
Mross, K.1
Stefanic, M.2
Gmehling, D.3
-
16
-
-
84891835786
-
Molecular-targeted agents combination therapy for cancer: developments and potentials
-
Li F, Zhao C, Wang L. Molecular-targeted agents combination therapy for cancer: developments and potentials. Int J Cancer 2014; 134: 1257-1269.
-
(2014)
Int J Cancer
, vol.134
, pp. 1257-1269
-
-
Li, F.1
Zhao, C.2
Wang, L.3
-
17
-
-
82055198571
-
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients
-
Bousquet G, Alexandre J, Le Tourneau C et al. Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer 2011; 105: 1640-1645.
-
(2011)
Br J Cancer
, vol.105
, pp. 1640-1645
-
-
Bousquet, G.1
Alexandre, J.2
Le Tourneau, C.3
-
18
-
-
77958038695
-
Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors
-
Okamoto I, Kaneda H, Satoh T et al. Phase I safety, pharmacokinetic, and biomarker study of BIBF 1120, an oral triple tyrosine kinase inhibitor in patients with advanced solid tumors. Mol Cancer Ther 2010; 9: 2825-2833.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 2825-2833
-
-
Okamoto, I.1
Kaneda, H.2
Satoh, T.3
-
19
-
-
0003808139
-
-
Version 3.0, DCTD, NCI, NIH, DHHS (20 May 2014, date last accessed)
-
Common Terminology Criteria For Adverse Events (CTCAE). Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf (20 May 2014, date last accessed).
-
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events
-
-
-
20
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
-
(2009)
Eur J Cancer
, vol.45
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
-
21
-
-
84867582561
-
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors
-
Brell JM, Krishnamurthi SS, Rath L et al. Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012; 70: 547-553.
-
(2012)
Cancer Chemother Pharmacol
, vol.70
, pp. 547-553
-
-
Brell, J.M.1
Krishnamurthi, S.S.2
Rath, L.3
-
22
-
-
78650953061
-
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients
-
Davies JM, Dhruva NS, Walko CM et al. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer 2011; 71: 151-155.
-
(2011)
Lung Cancer
, vol.71
, pp. 151-155
-
-
Davies, J.M.1
Dhruva, N.S.2
Walko, C.M.3
|